| Co-Investigator(Kenkyū-buntansha) |
櫻井 大樹 千葉大学, 医学(系)研究科(研究院), 講師 (10375636)
関 直彦 千葉大学, 医学(系)研究科(研究院), 准教授 (50345013)
本橋 新一郎 千葉大学, 医学(系)研究科(研究院), 教授 (60345022)
福本 一郎 千葉大学, 医学部附属病院, 医員 (70748764)
|
|---|
| Budget Amount *help |
¥44,720,000 (Direct Cost: ¥34,400,000、Indirect Cost: ¥10,320,000)
Fiscal Year 2016: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2014: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2013: ¥10,530,000 (Direct Cost: ¥8,100,000、Indirect Cost: ¥2,430,000)
Fiscal Year 2012: ¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
|
|---|
| Outline of Final Research Achievements |
To develop an effective adjuvant treatment for head and neck cancer, we have conducted the following studies.
1,Scientific evaluation of the efficacy of the nasal submucosal administration of α-galactocylceramide(αGalCer) pulsed antigen presenting cells(APCs) to the patients with head and neck squamous cell carcinoma, 2, Clarification of characteristics of the anti-tumor immune suppression observed in the patients with head and neck cancer, 3 Basic studies to improve the anti-tumor immune suppression in the patients with head and neck cancer, 4 Development of αGalCer pulsed APCs administration in patients with non-squamous cell carcinoma of head and neck. The adjuvant treatment with the nasal submucosal administration of αGalCer pulsed APCs to the patients with advanced head and neck squamous cell carcinoma following the standard treatments to suppress the recurrence, has been admitted as an Advanced Treatment B recognized by the government and continues to show final results.
|
